Literature DB >> 15615636

Pathways of tau fibrillization.

Jeff Kuret1, Carmen N Chirita, Erin E Congdon, Theresa Kannanayakal, Guibin Li, Mihaela Necula, Haishan Yin, Qi Zhong.   

Abstract

New methods for analyzing tau fibrillization have yielded insights into the biochemical transitions involved in the process. Here we review the parallels between the sequential progression of tau fibrillization observed macroscopically in Alzheimer's disease (AD) lesions and the pathway of tau aggregation observed in vitro with purified tau preparations. In addition, pharmacological agents for further dissection of fibrillization mechanism and lesion formation are discussed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15615636     DOI： 10.1016/j.bbadis.2004.06.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  42 in total

Review 1.  Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease.

Authors:  Amandine E Bonnet; Yannick Marchalant
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

2.  Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants.

Authors:  Erin E Congdon; Sohee Kim; Jonathan Bonchak; Tanakorn Songrug; Anastasios Matzavinos; Jeff Kuret
Journal:  J Biol Chem       Date:  2008-03-21       Impact factor: 5.157

Review 3.  Inflammation and aging: can endocannabinoids help?

Authors:  Yannick Marchalant; Holly M Brothers; Gary L Wenk
Journal:  Biomed Pharmacother       Date:  2008-03-14       Impact factor: 6.529

4.  Quantitative characterization of heparin binding to Tau protein: implication for inducer-mediated Tau filament formation.

Authors:  Hai-Li Zhu; Cristina Fernández; Jun-Bao Fan; Frank Shewmaker; Jie Chen; Allen P Minton; Yi Liang
Journal:  J Biol Chem       Date:  2009-12-03       Impact factor: 5.157

5.  Combinatorial Tau pseudophosphorylation: markedly different regulatory effects on microtubule assembly and dynamic instability than the sum of the individual parts.

Authors:  Erkan Kiris; Donovan Ventimiglia; Mehmet E Sargin; Michelle R Gaylord; Alphan Altinok; Kenneth Rose; B S Manjunath; Mary Ann Jordan; Leslie Wilson; Stuart C Feinstein
Journal:  J Biol Chem       Date:  2011-02-02       Impact factor: 5.157

6.  Protein interaction module-assisted function X (PIMAX) approach to producing challenging proteins including hyperphosphorylated tau and active CDK5/p25 kinase complex.

Authors:  Dexin Sui; Xinjing Xu; Xuemei Ye; Mengyu Liu; Maxwell Mianecki; Chotirat Rattanasinchai; Christopher Buehl; Xiexiong Deng; Min-Hao Kuo
Journal:  Mol Cell Proteomics       Date:  2014-11-10       Impact factor: 5.911

7.  Inferring Mechanistic Parameters from Amyloid Formation Kinetics by Approximate Bayesian Computation.

Authors:  Eri Nakatani-Webster; Abhinav Nath
Journal:  Biophys J       Date:  2017-03-14       Impact factor: 4.033

8.  Identification of an aggregation-prone structure of tau.

Authors:  Shana Elbaum-Garfinkle; Elizabeth Rhoades
Journal:  J Am Chem Soc       Date:  2012-10-01       Impact factor: 15.419

Review 9.  Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.

Authors:  Carlo Ballatore; Kurt R Brunden; Donna M Huryn; John Q Trojanowski; Virginia M-Y Lee; Amos B Smith
Journal:  J Med Chem       Date:  2012-09-28       Impact factor: 7.446

10.  Three repeat isoforms of tau inhibit assembly of four repeat tau filaments.

Authors:  Stephanie J Adams; Michael A DeTure; Melinda McBride; Dennis W Dickson; Leonard Petrucelli
Journal:  PLoS One       Date:  2010-05-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.